Pharmacogenomics and breast cancer

Area of Science:

• Genomics and Cancer Research
• Pharmacogenomics
• Oncology

Background:

• Germline variants contribute to breast cancer susceptibility and variable responses to therapy.
• Both high-penetrance mutations and cumulative low-risk polymorphisms play roles in hereditary and sporadic breast cancer.
• Genetic variations impact pathways involved in DNA repair, metabolism, and cellular adhesion.

Purpose of the Study:

• To explore the role of germline variants in breast cancer susceptibility and treatment response.
• To highlight the potential of pharmacogenomics in tailoring breast cancer therapies.
• To discuss how genetic insights can personalize cancer management.

Main Methods:

• Analysis of germline variants in genes related to breast cancer pathways.
• Identification of polymorphisms in genes affecting drug metabolism, transport, and targets.
• Examination of variants in DNA repair and radiation response genes.

Main Results:

• Germline polymorphisms in drug-metabolizing enzymes, transporters, and targets predict treatment toxicity and efficacy.
• Variants in DNA repair and radiation response genes can predict response to radiation therapy.
• Genomic approaches are increasingly integrated into breast cancer management.

Conclusions:

• Germline genetic variations are crucial for understanding breast cancer risk and predicting treatment outcomes.
• Pharmacogenomics offers a powerful tool for individualized breast cancer treatment, optimizing efficacy and minimizing toxicity.
• The integration of genomics is transforming breast cancer prevention and treatment strategies.